Higher objective responses by hepatic arterial infusion chemotherapy following atezolizumab and bevacizumab failure than when used as initial therapy in hepatocellular carcinoma: a retrospective study.

Jae-Sung YooJi Hoon KimHee Sun ChoJi Won HanJeong Won JangJong Young ChoiSeung Kew YoonSuho KimJung Suk OhHo Jong ChunPil-Soo Sung

Published in: Abdominal radiology (New York) (2024)

Although no significant difference was observed for OS and PFS, the ORR of patients in the HAIC group after the failure of atezo-bev therapy was superior to that of newly diagnosed patients. HAIC may prolong survival in patients with HCC after atezo-bev treatment failure.

Keyphrases

newly diagnosed
end stage renal disease
ejection fraction
chronic kidney disease
peritoneal dialysis
prognostic factors
low dose
patient reported outcomes
bone marrow
rectal cancer